Ono Pharmaceutical (OTCMKTS:OPHLF) Hits New 52-Week High – Time to Buy?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $15.22 and last traded at $15.22, with a volume of 1350 shares. The stock had previously closed at $14.00.

Ono Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.50 and a current ratio of 2.99. The stock has a market cap of $7.15 billion, a price-to-earnings ratio of 21.74 and a beta of 0.24. The company’s 50 day simple moving average is $13.56 and its 200 day simple moving average is $12.13.

Ono Pharmaceutical (OTCMKTS:OPHLF) last released its earnings results on Thursday, October 30th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Ono Pharmaceutical had a return on equity of 6.13% and a net margin of 9.75%.The firm had revenue of $876.10 million during the quarter, compared to the consensus estimate of $790.87 million.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.